FIELD: medicine.
SUBSTANCE: system has at least one steroid hormone and propylene glycol monocaprylate as penetration accelerator. The steroid hormone is enclosed into polymer matrix. Transdermal system is to be used as hormone-substituting therapy and contraception means.
EFFECT: increased steroid hormone penetration through skin; reduced transdermal system application area.
8 cl
| Title | Year | Author | Number |
|---|---|---|---|
| TRANSCUTANEOUS THERAPEUTIC SYSTEMS CONTAINING SEXUAL STEROIDS | 1995 |
|
RU2154455C2 |
| METHOD OF PREPARING DOSING UNITS BY WET GRANULATION METHOD | 1995 |
|
RU2166936C2 |
| INTERRUPTED HORMONE-SUBSTITUTION THERAPY WITH LOW ESTROGEN DOSAGES | 2000 |
|
RU2245713C2 |
| MULTIPHASE PHARMACEUTICAL PREPARATION FOR OVULATION INHIBITION IN MAMMAL | 2005 |
|
RU2396082C2 |
| PHARMACEUTICAL COMPOSITION, METHOD FOR PREPARING IT AND MULTIPHASE PHARMACEUTICAL PREPARATION FOR OVULATION INHIBITION IN MAMMAL | 2010 |
|
RU2482853C2 |
| ADMINISTRATION OF ANDROGENIC STEROIDS TO WOMEN BY NON-ORAL ROUTE | 2000 |
|
RU2234920C2 |
| ESTRADIOL-CONTAINING TRANSDERMAL THERAPEUTIC SYSTEM | 1994 |
|
RU2140784C1 |
| COMBINED PREPARATION FOR CONTRACEPTION, PHARMACEUTICAL CONTAINER FOR CONTRACEPTION | 1994 |
|
RU2122854C1 |
| METHOD FOR MANUFACTURE OF MEDICINE FOR TRANSDERMAL ADMINISTRATION | 1990 |
|
RU2044541C1 |
| PERCUTANEOUS DRUG DELIVERY COMPOSITION (VERSIONS), METHOD OF PRODUCTION AND APPLICATION | 2002 |
|
RU2358699C2 |
